MTL-STING / MiNA Therap - LARVOL DELTA

MTL-STING increases STING expression and potentiates efficacy of checkpoint inhibitor in murine preclinical model (ESMO 2022) - "In the first preclinical proof of concept study, the murine surrogate of MTL-STING combined with PD-1 antibody resulted in early inhibition of tumor growth and was the only group to regress tumor below pre-treatment sizes. Conclusions MTL-STING is expected to enter phase I in 2023."

Checkpoint inhibition • IO biomarker • Preclinical • Oncology • STING

MTL-STING restores endogenous STING expression for improving efficacy of cancer therapeutics (AACR 2022) - "NOV340 liposomes have previously been clinically validated to efficiently deliver saRNA to myeloid cells, which is the critical cellular subset to benefit from STING activation from an anti-tumor perspective. MTL-STING is pre-clinical development as a combination treatment administered intra-tumorally and is expected to enter Phase 1 in 2023."

Clinical • Oncology • STING

MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy (Businesswire) - "The preclinical data presented at AACR demonstrated that MTL‑STING upregulated STING mRNA production by more than fivefold, consistent with the activity required to restore STING to homeostatic levels in cancer patients. Importantly, upregulation of STING mRNA was durable, leading to increased levels of STING protein and downstream functional activation of innate immune pathways. MTL-STING is initially being developed as a combination treatment for solid tumour malignancies, with the expectation to enter Phase 1 evaluation in 2023."

New P1 trial • Preclinical • Oncology • Solid Tumor